Renal protection in chronic kidney disease: Hypoxia-inducible factor activation vs. angiotensin II blockade

American Journal of Physiology - Renal Physiology

Volumn 299, Issue 6, 2010, Pages

  Deng, Aihua ^a   Arndt, Mary Ann K ^a   Satriano, Joseph ^a   Singh, Prabhleen ^a   Rieg, Timo ^a   Thomson, Scott ^a   Tang, Tong ^a   Blantz, Roland C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Heme oxygenase 1; Kidney oxygen consumption; Subtotal nephrectomy; Vascular endothelial growth factor

Indexed keywords

ANGIOTENSIN II; BROXURIDINE; CAPTOPRIL; CARBONATE DEHYDRATASE IX; COBALT CHLORIDE; DIMETHYLOXALYGLYCINE; ERYTHROPOIETIN; GLUCOSE TRANSPORTER 1; GLYCINE DERIVATIVE; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INULIN; LOSARTAN; MESSENGER RNA; OXYGEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY INFARCTION; KIDNEY TUBULE CELL; MALE; NEPHRECTOMY; NONHUMAN; OXYGEN CONSUMPTION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; WESTERN BLOTTING;

EID: 78649962039     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00153.2010     Document Type: Article

References (47)

1. Aizawa T, Ishizaka N, Taguchi J, Nagai R, Mori I, Tang SS, Ingelfinger JR, Ohno M. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension 35: 800-806, 2000. (Pubitemid 30165329)
2. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, Weir EK. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF- 1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 294: H570-H578, 2008. (Pubitemid 351253263)
3. Badr GA, Zhang JZ, Tang J, Kern TS, Ismail-Beigi F. Glut1 and glut3 expression, but not capillary density, is increased by cobalt chloride in rat cerebrum and retina. Brain Res Mol Brain Res 64: 24-33, 1999. (Pubitemid 29049232)
4. Beck I, Weinmann R, Caro J. Characterization of hypoxia-responsive enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood 82: 704-711, 1993. (Pubitemid 23221646)
5. Bernhardt WM, Gottmann U, Doyon F, Buchholz B, Campean V, Schodel J, Reisenbuechler A, Klaus S, Arend M, Flippin L, Willam C, Wiesener MS, Yard B, Warnecke C, Eckardt KU. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci USA 106: 21276-21281, 2009.
6. Brown GC, Borutaite V. Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic Biol Med 33: 1440-1450, 2002. (Pubitemid 35351587)
7. Castilla MA, Caramelo C, Gazapo RM, Martin O, Gonzalez-Pacheco FR, Tejedor A, Bragado R, Arroyo MV. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci 67: 1003-1013, 2000.
8. Deng A, Miracle CM, Lortie M, Satriano J, Gabbai FB, Munger KA, Thomson SC, Blantz RC. Kidney oxygen consumption, carbonic anhydrase, and proton secretion. Am J Physiol Renal Physiol 290: F1009-F1015, 2006.
9. Deng A, Miracle CM, Suarez JM, Lortie M, Satriano J, Thomson SC, Munger KA, Blantz RC. Oxygen consumption in the kidney: effects of nitric oxide synthase isoforms and angiotensin II. Kidney Int 68: 723-730, 2005.
10. Deng A, Tang T, Singh P, Wang C, Satriano J, Thomson SC, Blantz RC. Regulation of oxygen utilization by angiotensin II in chronic kidney disease. Kidney Int 75: 197-204, 2009.
11. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate- dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 281: 15215-15226, 2006.
12. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001.
13. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242: 1412-1415, 1988.
14. Gossmann J, Burkhardt R, Harder S, Lenz T, Sedlmeyer A, Klinkhardt U, Geiger H, Scheuermann EH. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int 60: 83-86, 2001.
15. Gossmann J, Thurmann P, Bachmann T, Weller S, Kachel HG, Schoeppe W, Scheuermann EH. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 50: 973-978, 1996.
16. Gunaratnam L, Bonventre JV. HIF in kidney disease and development. J Am Soc Nephrol 20: 1877-1887, 2009.
17. Harris DC, Chan L, Schrier RW. Remnant kidney hypermetabolism and progression of chronic renal failure. Am J Physiol Renal Fluid Electrolyte Physiol 254: F267-F276, 1988.
18. Haugen EN, Croatt AJ, Nath KA. Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int 58: 144-152, 2000.
19. Haverty TP, Kelly CJ, Hines WH, Amenta PS, Watanabe M, Harper RA, Kefalides NA, Neilson EG. Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. J Cell Biol 107: 1359-1368, 1988.
20. Heidbreder M, Frohlich F, Johren O, Dendorfer A, Qadri F, Dominiak P. Hypoxia rapidly activates HIF-3alpha mRNA expression. FASEB J 17: 1541-1543, 2003.
21. Hewitson KS, McNeill LA, Elkins JM, Schofield CJ. The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans 31: 510-515, 2003.
22. Heyman SN, Khamaisi M, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol 28: 998-1006, 2008.
23. Imagawa S, Nakano Y, Obara N, Suzuki N, Doi T, Kodama T, Nagasawa T, Yamamoto M. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J 17: 1742-1744, 2003.
24. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457, 2001.
25. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12: 1434-1447, 2001. (Pubitemid 32666326)
26. Koivisto A, Pittner J, Froelich M, Persson AE. Oxygen-dependent inhibition of respiration in isolated renal tubules by nitric oxide. Kidney Int 55: 2368-2375, 1999. (Pubitemid 29256490)
27. La Ferla K, Reimann C, Jelkmann W, Hellwig-Burgel T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J 16: 1811-1813, 2002.
28. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 293: 90-95, 2005.
29. Mole DR, Schlemminger I, McNeill LA, Hewitson KS, Pugh CW, Ratcliffe PJ, Schofield CJ. 2-Oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg Med Chem Lett 13: 2677-2680, 2003. (Pubitemid 36851548)
30. Nagel S, Papadakis M, Chen R, Hoyte LC, Brooks KJ, Gallichan D, Sibson NR, Pugh C, Buchan AM. Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2010 Apr 21. [Epub ahead of print].
31. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17-25, 2006.
32. Nath KA, Croatt AJ, Hostetter TH. Oxygen consumption and oxidant stress in surviving nephrons. Am J Physiol Renal Fluid Electrolyte Physiol 258: F1354-F1362, 1990.
33. Onoyama K, Sanai T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol 13, Suppl 3: S27-30, 1989.
34. Piret JP, Mottet D, Raes M, Michiels C. CoCl2, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann NY Acad Sci 973: 443-447, 2002. (Pubitemid 36125050)
35. Prescott AG, Lloyd MD. The iron(II) and 2-oxoacid-dependent dioxygenases and their role in metabolism. Nat Prod Rep 17: 367-383, 2000.
36. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003. (Pubitemid 37337595)
37. Schiffer M, Park JK, Tossidou I, Bartels J, Shushakova N, Menne J, Fliser D. Erythropoietin prevents diabetes-induced podocyte damage. Kidney Blood Press Res 31: 411-415, 2008.
38. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017, 2004.
39. Schweda F, Blumberg FC, Schweda A, Nabel C, Holmer SR, Riegger GA, Pfeifer M, Kramer BK. Effects of chronic hypoxia on renal PDGF-A, PDGF-B, and VEGF gene expression in rats. Nephron 86: 161-166, 2000.
40. Semenza GL. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 405: 1-9, 2007.
41. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 88: 5680-5684, 1991.
42. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
43. Song YR, You SJ, Lee YM, Chin HJ, Chae DW, Oh YK, Joo KW, Han JS, Na KY. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant 25: 77-85.
44. Suga S, Kim YG, Joly A, Puchacz E, Kang DH, Jefferson JA, Abraham JA, Hughes J, Johnson RJ, Schreiner GF. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int 60: 1297-1308, 2001.
45. Tanaka T, Kojima I, Ohse T, Ingelfinger JR, Adler S, Fujita T, Nangaku M. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 85: 1292-1307, 2005. (Pubitemid 41348643)
46. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82: 3610-3615, 1993.
47. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55: 808-820, 1999.